May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa tunnels have different microenvironments, suggesting targeted treatments could be more effective.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa tunnels have different microenvironments, suggesting targeted treatments could be more effective.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Hidradenitis suppurativa tunnels have different microenvironments, suggesting targeted treatments could be more effective.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
April 2026 in “Aesthetic Surgery Journal Open Forum” Future hair loss treatments focus on non-invasive and regenerative methods, needing more clinical trials.
April 2026 in “Clinical and Experimental Dermatology” Alopecia areata causes significant emotional distress, requiring treatments that focus on mental health and social support, not just hair regrowth.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
April 2026 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata deeply affects life beyond appearance, and effective treatments can restore confidence and improve quality of life.
April 2026 in “International Journal of Drug Delivery Technology” Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
April 2026 in “Antibodies” The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.
April 2026 in “Journal of Inflammation Research” Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
March 2026 in “Mendeley Data” rwSALT provides precise hair regrowth measurement from scalp photos.
March 2026 in “Mendeley Data” rwSALT accurately measures hair regrowth in alopecia areata using scalp photos.
March 2026 in “International Journal of Innovative Technologies in Social Science” Vitiligo is a systemic disease with psychological effects, and new treatments focus on personalized care.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
March 2026 in “Mendeley Data” Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
March 2026 in “Actas Dermo-Sifiliográficas” JAK inhibitors are recommended for severe alopecia areata if corticosteroids fail.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
March 2026 in “Biomedicines” New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Alopecia affects mental health, causing depression and anxiety, but new treatments can improve both hair growth and quality of life.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Alopecia affects mental health, causing depression and anxiety, but new treatments can help improve both hair growth and quality of life.
February 2026 in “Journal of Allergy and Clinical Immunology” Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.
February 2026 in “Dove Medical Press (Taylor and Francis Group)” Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.